L-DOPA

L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

Product Specifications

CAS Number

[59-92-7]

Product Name Alternative

Levodopa; 3,4-Dihydroxyphenylalanine

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Dopamine Receptor; Endogenous Metabolite

Type

Natural Products

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/L-DOPA.html

Purity

99.98

Solubility

0.1 M HCl : 20 mg/mL (ultrasonic; warming; adjust pH to 2 with HCl; heat to 60°C) |DMSO : 2 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 1 mg/mL (ultrasonic)

Smiles

N[C@@H](CC1=CC(O)=C(C=C1)O)C(O)=O

Molecular Formula

C9H11NO4

Molecular Weight

197.19

Precautions

H302, H315, H319, H335

References & Citations

[1]Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38 (12) :2405-10.|[2]Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 2008;14 (4) :273-80. Epub 2007 Nov 7.|[3]Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 3;10:237.|[4]Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54 (2) :330-5.|[5]M Lundblad, et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol. 2005 Jul;194 (1) :66-75. |[6]Jie Zhang, et al. Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. Brain Res. 2003 Dec 12;993 (1-2) :54-8.